EP2046299A1 — Controlled-release formulations
Assigned to Mutual Pharmaceutical Co Inc · Expires 2009-04-15 · 17y expired
What this patent protects
Disclosed herein are controlled-release formulations which exhibit substantially zero-order release kinetics. The formulations include a core comprising a core active agent and a wax excipient substantially coated with an extended-release coating. The formulation optionally inclu…
USPTO Abstract
Disclosed herein are controlled-release formulations which exhibit substantially zero-order release kinetics. The formulations include a core comprising a core active agent and a wax excipient substantially coated with an extended-release coating. The formulation optionally includes an immediate-release portion comprising an immediate-release active agent in the form of, for example, a coating disposed on at least a portion of the core. Further disclosed are fexofenadine/pseudoephedrine combination formulations, which exhibit substantially no food effect.
Drugs covered by this patent
- OxyContin (oxycodone) · Purdue Pharma
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.